<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174118</url>
  </required_header>
  <id_info>
    <org_study_id>DCR-A1AT-101</org_study_id>
    <nct_id>NCT04174118</nct_id>
  </id_info>
  <brief_title>Study of DCR-A1AT in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase 1 Single Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered Belcesiran in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dicerna Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dicerna Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to test an experimental study drug (belcesiran, also known as&#xD;
      DCR-A1AT). This drug is being tested to see if it helps people with a rare condition known as&#xD;
      Alpha-1 Antitrypsin Deficiency, or A1ATD. Prior to initiation of this study belcesiran had&#xD;
      not yet been tested in humans. All study participants will be randomly assigned to either&#xD;
      receive the study drug or a placebo. This will allow for the sponsor to compare the effects&#xD;
      of the study drug with that of the placebo. A placebo looks like the study drug but does not&#xD;
      contain any of the study drug.&#xD;
&#xD;
      The main purpose of the first part of the study is to evaluate the safety profile of the&#xD;
      study drug in people who do not have A1ATD. This part of the study will also help find the&#xD;
      dose of the study drug that has an acceptable safety profile for testing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A1ATD- associated liver disease is a progressive Alpha-1 Antitrypsin-Deficiency Associated&#xD;
      Liver Disease condition resulting in liver fibrosis, cirrhosis, and hepatocellular carcinoma.&#xD;
      The lack of functional A1AT in individuals with PiZZ genotype, in conjunction with other&#xD;
      precipitating factors, can lead to unchecked activity in neutrophil elastases in the alveoli;&#xD;
      causing emphysema and chronic obstructive pulmonary disease (COPD). This loss-of-function&#xD;
      mechanism can be addressed with intravenous augmentation therapy, which aims to substitute&#xD;
      the missing A1AT by infusing alpha1 proteinase inhibitor (A1PI), purified from pooled human&#xD;
      plasma.&#xD;
&#xD;
      While augmentation therapy can address the loss of A1AT in the lungs, no treatment exists for&#xD;
      the associated liver disease.&#xD;
&#xD;
      Given the severity of the disease, with approximately 10% of affected patients developing&#xD;
      liver cirrhosis and a subgroup of those patients in need of liver transplantation, and lack&#xD;
      of an effective treatment that addresses the toxic hepatic &quot;gain-of-function&quot; mechanism,&#xD;
      there is an urgent unmet medical need to develop a therapy that can help in this particular&#xD;
      patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>approximately up to 2 months</time_frame>
    <description>The incidence of adverse events (AE), serious adverse events (SAE), DLT, and AE leading to study drug discontinuation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating safety and tolerability through physical exams</measure>
    <time_frame>approximately up to 2 months</time_frame>
    <description>The incidence of clinically significant physical examination (PE) findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in 12-lead electrocardiograms (ECG)</measure>
    <time_frame>approximately up to 2 months</time_frame>
    <description>Absolute QTc &gt; 500 msec and/or QTc change of &gt; 60 msec from baseline will be evaluated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics (PK) of belcesiran</measure>
    <time_frame>up to Day 3</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics (PK) of belcesiran</measure>
    <time_frame>up to 57 days</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics (PK) of belcesiran</measure>
    <time_frame>up to 57 days</time_frame>
    <description>Area under the curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics (PK) of belcesiran</measure>
    <time_frame>up to Day 3</time_frame>
    <description>Area under the curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics (PK) of belcesiran</measure>
    <time_frame>up to Day 3</time_frame>
    <description>Minimum observed concentration (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics (PK) of belcesiran</measure>
    <time_frame>up to 57 days</time_frame>
    <description>Minimum observed concentration (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics (PK) of belcesiran</measure>
    <time_frame>up to 57 days</time_frame>
    <description>Time to maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics (PK) of belcesiran</measure>
    <time_frame>up to Day 3</time_frame>
    <description>Time to maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics (PK) of belcesiran</measure>
    <time_frame>up to Day 3</time_frame>
    <description>Terminal elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plama pharmacokinetics (PK) of belcesiran</measure>
    <time_frame>up to 57 days</time_frame>
    <description>Terminal elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in protein concentration</measure>
    <time_frame>up to day 57</time_frame>
    <description>Changes in A1AT protein concentrations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Alpha 1-Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>belcesiran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will be administered a single dose of belcesiran.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers will be administered a single dose of matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>belcesiran</intervention_name>
    <description>belcesiran will be administered subcutaneously (SC) at dose levels planned.</description>
    <arm_group_label>belcesiran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female aged 18 to 55 years, inclusive. Female participants must be either&#xD;
             surgically sterile or postmenopausal. No women of childbearing potential are eligible&#xD;
             for enrollment.&#xD;
&#xD;
          -  Overtly Healthy, as determined by the investigator.&#xD;
&#xD;
          -  Serum A1AT protein concentration &gt;100 mg/dL&#xD;
&#xD;
          -  Adequate forced expiratory volume in one second (FEV1) and adequate FEV1/forced vital&#xD;
             capacity (FVC) ratio&#xD;
&#xD;
          -  Non-smokers with a &lt;2 pack-year history and smoking cessation for at least 6 months&#xD;
             with a negative urinary cotinine test a screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any condition or comorbidities that would interfere with study compliance&#xD;
             or data interpretation or potentially affect participant safety&#xD;
&#xD;
          -  Clinically significant abnormal laboratory tests&#xD;
&#xD;
          -  Received an experimental drug within past 4 months&#xD;
&#xD;
          -  Prior to use of RNAi drug or oligonucleotide-based therapy&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV), hepatitis C virus (HCV), or Hepatitis B&#xD;
             (HBV)&#xD;
&#xD;
          -  Serum creatinine or estimated glomerular filtration rate (eGFR) outside normal&#xD;
             reference ranges.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hardean Achneck, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dicerna Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dicerna Pharmaceuticals</last_name>
    <phone>617-621-8097</phone>
    <email>medicalinfo@dicerna.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ed Gane, MD</last_name>
      <phone>+64 9 3733474</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Consultants AB</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

